Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies.
Scott W RobertsTara Laura Brandt ElvangLaila SyedMarianne Bork SamuelsenEva Lisby Arp-HansenHenrik Kim NielsenIda Katrine LundDorte Lunøe DünweberNicolai Listov-SaabyeDorte Bjørn-LarsenAnette HjelmsmarkTue Anker MikkelsenPublished in: Therapeutic innovation & regulatory science (2022)
Keyphrases